JP2009522368A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522368A5
JP2009522368A5 JP2008549583A JP2008549583A JP2009522368A5 JP 2009522368 A5 JP2009522368 A5 JP 2009522368A5 JP 2008549583 A JP2008549583 A JP 2008549583A JP 2008549583 A JP2008549583 A JP 2008549583A JP 2009522368 A5 JP2009522368 A5 JP 2009522368A5
Authority
JP
Japan
Prior art keywords
hcv
agent
composition
complex
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549583A
Other languages
English (en)
Japanese (ja)
Other versions
JP5405832B2 (ja
JP2009522368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000362 external-priority patent/WO2007081848A2/en
Publication of JP2009522368A publication Critical patent/JP2009522368A/ja
Publication of JP2009522368A5 publication Critical patent/JP2009522368A5/ja
Application granted granted Critical
Publication of JP5405832B2 publication Critical patent/JP5405832B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549583A 2006-01-04 2007-01-04 Ｈｃｖ特異的なｔ細胞の活性化 Expired - Fee Related JP5405832B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75635406P 2006-01-04 2006-01-04
US60/756,354 2006-01-04
US79984006P 2006-05-11 2006-05-11
US60/799,840 2006-05-11
US84008206P 2006-08-25 2006-08-25
US60/840,082 2006-08-25
PCT/US2007/000362 WO2007081848A2 (en) 2006-01-04 2007-01-04 Activation of hcv-specific t cells

Publications (3)

Publication Number Publication Date
JP2009522368A JP2009522368A (ja) 2009-06-11
JP2009522368A5 true JP2009522368A5 (enExample) 2011-02-10
JP5405832B2 JP5405832B2 (ja) 2014-02-05

Family

ID=38256946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549583A Expired - Fee Related JP5405832B2 (ja) 2006-01-04 2007-01-04 Ｈｃｖ特異的なｔ細胞の活性化

Country Status (6)

Country Link
US (1) US8178086B2 (enExample)
EP (1) EP1981537B1 (enExample)
JP (1) JP5405832B2 (enExample)
CA (1) CA2636032C (enExample)
ES (1) ES2551113T3 (enExample)
WO (1) WO2007081848A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578520B (zh) 2006-10-18 2015-09-16 哈佛学院院长等 基于形成图案的多孔介质的横向流动和穿过生物测定装置、及其制备方法和使用方法
CA2719322C (en) 2008-03-27 2018-11-27 President And Fellows Of Harvard College Cotton thread as a low-cost multi-assay diagnostic platform
AU2009228012A1 (en) 2008-03-27 2009-10-01 President And Fellows Of Harvard College Paper-based microfluidic systems
CA2719320A1 (en) 2008-03-27 2009-10-01 President And Fellows Of Harvard College Three-dimensional microfluidic devices
US9829488B2 (en) 2008-03-27 2017-11-28 President And Fellows Of Havard College Paper-based cellular arrays
CA2754577C (en) 2009-03-06 2018-07-10 President And Fellows Of Harvard College Microfluidic, electrochemical devices
CU24112B1 (es) * 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Antígenos vacunales quiméricos contra el virus de la hepatitis c
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
AU2022307932A1 (en) * 2021-07-06 2024-02-08 The Trustees Of The University Of Pennsylvania P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US6054424A (en) * 1998-04-15 2000-04-25 Church & Dwight Co., Inc. Process for the production of a liquid laundry detergent composition of desired viscosity containing nonionic and anionic surfactants
US20050074465A1 (en) * 1999-11-24 2005-04-07 Michael Houghton HCV fusion proteins with modified NS3 domains
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US20060088819A1 (en) * 2004-05-17 2006-04-27 Chiron Corporation Truncated hepatitis C virus NS5 domain and fusion proteins comprising same

Similar Documents

Publication Publication Date Title
Lechmann et al. Vaccine development for hepatitis C
Encke et al. DNA vaccines
Bellier et al. Virus-like particle-based vaccines against hepatitis C virus infection
JP2009522368A5 (enExample)
JP2006504644A5 (enExample)
Inchauspé et al. Development of a hepatitis C virus vaccine
JP2005510244A5 (enExample)
Memarnejadian et al. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine
Shayeghpour et al. Hepatitis C virus DNA vaccines: a systematic review
Zhang et al. Silk fibroin-coated nano-MOFs enhance the thermal stability and immunogenicity of HBsAg
AU2013339846B2 (en) Chimeric vaccine antigens against hepatitis C virus
CN110049993A (zh) 组装的糖蛋白
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
CN101043902B (zh) 针对丙型肝炎病毒的疫苗组合物
Zhu et al. Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160
Hill et al. The Cellular Immune Response
Kardani et al. The next generation of HCV vaccines: a focus on novel adjuvant development
Guan et al. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes
Karayiannis et al. Hepatitis vaccines
Luo et al. Recent advances in clinical trials of HCV vaccines
Jahantigh et al. Advancing peptide-based vaccines against viral pathogens: a narrative review
Martin et al. Hepatitis C vaccines
Hynicka State of the art of HCV vaccines in the era of new antivirals
Saeedi et al. Enhanced immune responses of a hepatitis C virus core DNA vaccine by co-inoculating interleukin-12 expressing vector in mice
Bailey et al. Flaviviridae 132, 176 Flavivirus 176 Genetic immunization 78 Hepacare 88 Hepatitis B 65, 78